Trileucine Improves Aerosol Performance and Stability of Spray-Dried Powders for Inhalation

DAVID LECHUGA-BALLESTEROS, CHATAN CHARAN, CHERYL L.M. STULTS, CYNTHIA L. STEVENSON, DANFORTH P. MILLER, REINHARD VEHRING, VATHANA TEP, MEI-CHANG KUO

Nektar Therapeutics, 150 Industrial Road San Carlos, California 94070

Received 17 November 2006; revised 23 January 2007; accepted 13 March 2007

Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.21078

ABSTRACT: For particles to be useful medicinal aerosols, not only their aerodynamic diameter has to be on the order of a few micrometers but also they have to be chemically and physically stable. Manufacture of respirable particles is a technical challenge because as particles are reduced in size by conventional milling techniques, their cohesiveness greatly increases and physical and chemical stability is often compromised by the formation of amorphous material. In the present study, we describe the use of trileucine for the preparation of dry powders suitable for inhalation via spray drying of a wide range of drugs (i.e., asthma therapeutics such as albuterol and cromolyn, and anti-infectives such as netilmicin and gentamicin, as well as therapeutic proteins and peptides such as human growth hormone and salmon calcitonin). The glass transition of spray-dried trileucine is dependent on the pH and can be correlated with the proportion of the anion, cation, and zwitterion concentration in solution. Trileucine glass transition is relatively high (≈104°C) enabling long-term room temperature stability. The solubility of trileucine is dependent on the pH and is lowest at neutral pH (≈6.8 mg/mL). Trileucine’s low aqueous solubility enables the formation of low-density corrugated particles and promotes the formation of trileucine coated spray-dried particles, resulting in superior aerosol performance. Trileucine is surface active and promotes the formation of spray-dried powders with a reduced cohesiveness as demonstrated by a decrease in the measured surface energy which correlates with an observed improvement in aerosol performance. Additionally, trileucine competes with the protein on the air/water interface resulting in an additional depression of surface tension in solution which correlates with a decreased denaturation and aggregation in the solid state. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci

Keywords: dry powder inhalers; spray drying; formulation; stability; protein; antibiotic; asthma; aggregation; surface activity; solubility; aerosol; emitted dose; dispersibility; size distribution; surface concentration; surface energy; trileucine; glass transition

INTRODUCTION

The use of spray drying to prepare dry powders for inhalation of small molecules, peptides and proteins has been established in recent years. The main aim has been to produce powders that can be easily dispersed to form an aerosol, without the use of a carrier, to enable the delivery of pharmaceuticals into the lung for local or systemic absorption into the human body. This is typically achieved by producing a low-density fine powder with a mass median aerodynamic diameter (MMAD), usually less than 3 μm. The fine powders can be filled into capsules or blister packages, and then redispersed using an aerosolization